Open/Aftercare Treatment for Participants Diagnosed With Obsessive Compulsive Disorder
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03511534 |
Recruitment Status :
Recruiting
First Posted : April 30, 2018
Last Update Posted : May 14, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
OCD | Behavioral: Psychotherapy Other: Pharmacotherapy | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 200 participants |
Allocation: | Non-Randomized |
Intervention Model: | Single Group Assignment |
Intervention Model Description: | Participants will choose to enter the psychotherapy or pharmacotherapy arm. |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Open/Aftercare Treatment for Participants Diagnosed With Obsessive Compulsive Disorder |
Actual Study Start Date : | June 23, 2017 |
Estimated Primary Completion Date : | June 2025 |
Estimated Study Completion Date : | June 2026 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Psychotherapy
Participants will receive evidenced based psychotherapy by a trained psychologist
|
Behavioral: Psychotherapy
Evidenced based psychotherapy by a trained psychologist |
Active Comparator: Pharmacotherapy
Participants will receive pharmacotherapy by a psychiatrist
|
Other: Pharmacotherapy
Pharmacotherapy by a psychiatrist |
- Improvement in the severity of OCD symptoms as measured by the Yale-Brown Obsessive Compulsive Scale (YBOCS) [ Time Frame: Up to 14 weeks ]Improvement in OCD severity is measured by the YBOCS (Yale Brown Obsessive-Compulsive Scale), a gold standard measure of obsessions and compulsions. For the YBOCS the minimum units are 0 and Maximum units on the total scale are 40. The higher the number on the YBOCS, the more severe the symptoms. Response is defined as at least a 35% reduction on the YBOCS.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Ability to speak and understand English
- Capacity to consent (e.g. as determined by assessing the patient's understanding of the risks, benefits, and procedures of the study)
- Completed an active study protocol at the Rodriguez Lab at Stanford University
Exclusion Criteria:
- Children younger than 18
- Active suicidality

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03511534
Contact: Andrea Varias, MSHS | 650-723-4095 | ocdresearch@stanford.edu | |
Contact: Maria Filippou-Frye, MD, MBS | 650-723-4095 | mariafilippoufrye@stanford.edu |
United States, California | |
Stanford University | Recruiting |
Stanford, California, United States, 94305 | |
Contact: Andrea Varias, MSHS 650-723-4095 ocdresearch@stanford.edu | |
Contact: Maria Filippou-Frye, MD, MBS 650-723-4095 ocdresearch@stanford.edu |
Principal Investigator: | Carolyn Rodriguez, MD, PhD | Assistant Professor, Stanford University |
Responsible Party: | Carolyn Rodriguez, Assistant Professor, Stanford University |
ClinicalTrials.gov Identifier: | NCT03511534 |
Other Study ID Numbers: |
41165 |
First Posted: | April 30, 2018 Key Record Dates |
Last Update Posted: | May 14, 2020 |
Last Verified: | May 2020 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | No |
treatment, psychotherapy, pharmacotherapy |
Compulsive Personality Disorder Obsessive-Compulsive Disorder Personality Disorders Mental Disorders Anxiety Disorders |